Answers are grounded in this paper and cite their sources.
Parenteral prostacyclin pathway agent-induced thrombocytopenia may require dose reduction or therapy discontinuation to mitigate the adverse events. However, the pulmonary arterial hypertension (PAH) guidelines do not suggest any strategy to overcome treprostinil-induced thrombocytopenia. Selexipag is an oral, non-prostanoid, selective IP receptor agonist. This is the first case report proposing the use of selexipag, due to its minimal thrombocytopenia risk, when severe treprostinil-induced thrombocytopenia occurs in practice. A 66-year-old woman presented to the hospital with new-onset PAH and right ventricular dysfunction. Due to the high mortality risk, the patient was initially started on intravenous treprostinil. The clinical course was complicated by probable treprostinil-induced thrombocytopenia. Due to the need for prostacyclin pathway therapy, the decision was made to switch from intravenous treprostinil to oral selexipag. The nadir platelet count was 30,000/μL. Approximately 72 h after discontinuation of treprostinil and maintaining selexipag 1600 mcg twice daily, the platelet count improved to 46,000/μL on the day of discharge. Several days after discharge, the platelet count further improved to 55,000/μL. The repeated platelet count 1 month after discharge normalized to 329,000/μL. Our case report described the successful use of selexipag to overcome treprostinil-induced thrombocytopenia, owing to its limited effect on platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Kido et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: